Form 4: 89bio Director Sells Shares, Options in Roche Merger

89bio Director Charles McWherter disposed of all his common stock and stock options following the completion of the merger with Roche Holdings, Inc. for $14.50 cash plus CVRs.

Summary

• Charles McWherter, a Director of 89bio, Inc., reported the disposition of all his beneficially owned common stock and stock options.
• The transactions occurred on October 30, 2025, as a result of the merger of 89bio, Inc. with Roche Holdings, Inc.
• Roche Holdings, Inc., through its subsidiary Bluefin Merger Subsidiary, Inc., completed a tender offer for all outstanding shares of 89bio common stock.
• The offer price for each share was $14.50 in cash (the "Closing Amount") plus one non-tradeable Contingent Value Right (CVR).
• The CVRs represent the right to receive contingent payments of up to an aggregate of $6.00 per share upon the achievement of specified milestones.
• Following the tender offer, Bluefin Merger Subsidiary, Inc. merged into 89bio, Inc., making 89bio a wholly-owned subsidiary of Roche Holdings, Inc.
• All outstanding shares of 89bio were cancelled in exchange for the Offer Price.
• Outstanding stock options became fully vested and exercisable immediately prior to the merger.
• Unexercised options were cancelled and converted into a cash payment (Closing Amount minus exercise price, multiplied by the number of shares) plus one CVR per share, unless they were out-of-the-money.
• Options with an exercise price equal to or greater than $14.50 but less than $20.50 (Out of the Money Options) received no upfront cash but were converted into CVRs and could receive milestone payments.
• Options with an exercise price equal to or greater than $20.50 were cancelled without any payment.

Sentiment

Score: 7

Explanation: The sentiment is positive for shareholders who received a cash premium and potential upside from CVRs, reflecting a successful acquisition. However, the cancellation of deep out-of-the-money options and the non-tradeable nature of CVRs introduce some negative aspects for certain option holders and liquidity.

Positives

• Shareholders received $14.50 per share in cash, providing immediate liquidity.
• Shareholders and eligible option holders also received Contingent Value Rights (CVRs) for potential future payments of up to $6.00 per share, offering upside potential based on milestone achievements.
• All outstanding options became fully vested and exercisable prior to the merger, allowing holders to realize value.
• Options with an exercise price below the Closing Amount received a cash payment and CVRs.

Negatives

• Options with an exercise price equal to or greater than $20.50 were cancelled without any payment, resulting in a loss of value for those holders.
• Out-of-the-money options (exercise price >= $14.50 but < $20.50) did not receive an upfront cash payment, only CVRs, deferring potential value realization and introducing contingency.
• The CVRs are non-tradeable, limiting liquidity for the contingent payments.

Risks

• The CVRs are contingent on the achievement of specified milestones, meaning the full $6.00 per share may not be realized.
• The CVRs are non-tradeable, limiting the ability of holders to sell their rights before milestones are met.
• The value of the CVRs is subject to the terms and conditions of the CVR Agreement, which may contain complex provisions.

Future Outlook

The future outlook for former 89bio shareholders and eligible option holders includes potential additional payments of up to $6.00 per share via Contingent Value Rights (CVRs), contingent upon the achievement of specified milestones on or prior to applicable milestone outside dates.

Industry Context

This acquisition by Roche Holdings, Inc. of 89bio, Inc. reflects the ongoing consolidation and strategic M&A activity within the biotechnology and pharmaceutical sectors, particularly for companies with promising drug candidates or platforms. Larger pharmaceutical companies often acquire smaller biotech firms to bolster their pipelines and gain access to innovative therapies.

Comparison to Industry Standards

• The acquisition price of $14.50 cash plus CVRs up to $6.00 per share (total potential $20.50) represents a valuation for 89bio. Without specific financial performance data for 89bio in this filing, a direct comparison to industry benchmarks like price-to-sales or enterprise value-to-EBITDA multiples is not feasible.
• Contingent Value Rights (CVRs) are a common mechanism in biotech M&A, used to bridge valuation gaps and share future risks/rewards, especially for assets in clinical development. Recent examples include Merck's acquisition of Acceleron Pharma, where CVRs were used, or Sanofi's acquisition of Kadmon Holdings. The structure of the CVRs (non-tradeable, specific milestones) is typical for such arrangements.
• The treatment of stock options, including full vesting and conversion to cash/CVRs or cancellation for deep out-of-the-money options, aligns with standard practices in M&A transactions to address employee equity incentives.

Stakeholder Impact

• Shareholders: Received $14.50 per share in cash and one non-tradeable CVR per share, providing immediate value and potential future upside.
• Option Holders: Those with in-the-money options received cash and CVRs; those with out-of-the-money options received CVRs; those with deep out-of-the-money options had them cancelled without payment.
• Employees: Implied impact on employees of 89bio as it becomes a wholly-owned subsidiary of Roche, though specific details are not in this filing.
• Roche Holdings, Inc.: Successfully acquired 89bio, expanding its portfolio.

Next Steps

• Achievement of specified milestones for the Contingent Value Rights (CVRs) to trigger potential future payments.
• Integration of 89bio, Inc. as a wholly-owned subsidiary into Roche Holdings, Inc.

Key Dates

Recommendation

This Form 4 reports the completion of a merger and the disposition of shares and options by a director. The company, 89bio, Inc., is now a wholly-owned subsidiary of Roche Holdings, Inc., and its common stock is no longer publicly traded. Therefore, there is no longer an active market for ETNB shares to 'buy' or 'sell.' For former shareholders, the recommendation would have been to 'tender' their shares. For investors looking at Roche, this filing provides context on their acquisition strategy, but doesn't directly impact a recommendation for Roche's stock based solely on this Form 4. 'Hold' is the most appropriate for a company that has been acquired and delisted, as there's no further action to take regarding its shares.

Keywords

89bio, ETNB, Roche Holdings, Merger, Acquisition, Tender Offer, Contingent Value Rights, CVR, Stock Options, SEC Form 4, Beneficial Ownership, Biotechnology, Pharmaceuticals